Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-04 Disclosures
  • [Disclosure] SK Square (402340) – Decision on Issuance of Depositary Receipts / 2026-06-24 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Occurrence of Serious Accident / 2026-01-09 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Re-listing / 2024-09-24 Disclosures
  • [Disclosure] Celltrion (068270) – Share Retirement Decision / 2025-03-14 Disclosures
  • [Research] SK hynix (000660 / SKHY) – Kiwoom Securities | 2Q24 Earnings In Line · 3Q24 Consensus Miss Forecast · Marketperform Rating Maintained / 2024-07-26 RESEARCH
  • [Disclosure] Hanwha Systems (272210) – Execution of Single Sales or Supply Contract (Correction) / 2026-04-01 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Setting of Record Date or Period for Closure of Shareholder Register / 2024-12-16 Shipbuilding

[Disclosure] Wonik IPS (240810) – Consolidated Financial Results (Provisional) / 2024-11-07

Posted on November 7, 2024August 3, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Wonik IPS reported Q3 2024 consolidated revenue of KRW 184.6B and an operating profit of KRW 14.5B, turning to an operating profit both QoQ and YoY.

📊 [Key Disclosure Contents & Summary Metrics]

  • Performance Period:
    • Current Period: July 01, 2024 – September 30, 2024 (Q3 2024)
    • Cumulative Period: January 01, 2024 – September 30, 2024 (Cumulative Q3 2024)
  • Key Financial Metrics (Consolidated Basis):
    • Revenue:
      • Q3 2024: KRW 184.6B (KRW 184,587 million / +19.16% QoQ, +2.60% YoY)
      • Cumulative Q3: KRW 453.3B (KRW 453,322 million / -2.49% YoY)
    • Operating Profit:
      • Q3 2024: KRW 14.5B (KRW 14,466 million / Turned to Profit QoQ, Turned to Profit YoY)
      • Cumulative Q3: KRW -15.3B (KRW -15,338 million / Loss Narrowed by 49.09% YoY)
    • Profit Before Income Tax:
      • Q3 2024: KRW 3.8B (KRW 3,754 million / +17.60% QoQ, +4.92% YoY)
      • Cumulative Q3: KRW -13.0B (KRW -13,027 million / Loss Narrowed by 12.86% YoY)
    • Net Profit:
      • Q3 2024: KRW 8.5B (KRW 8,450 million / +20.26% QoQ, +109.31% YoY)
      • Cumulative Q3: KRW -7.0B (KRW -6,989 million / Loss Narrowed by 28.30% YoY)
  • Other Investment Considerations:
    • Figures are provisional and prepared under K-IFRS on a consolidated basis.
    • Subject to change based on the external auditor’s review.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Final Audit Figures and Financial Statements in Periodic Report

This disclosure presents provisional earnings results prior to the completion of the external auditor’s review for Q3 2024. Verifying whether there are any discrepancies between the provisional figures announced and the finalized metrics in the upcoming quarterly report is recommended. Detailed financial statements and explanatory notes can be checked in the upcoming Q3 quarterly report.

📢 Disclaimer & Source Notice

Source: This content is structured and rewritten based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Semiconductors, Disclosures

Post navigation

Previous Post: [Disclosure] ALTEOGEN (196170) – Decision on Merger / 2024-11-07
Next Post: [Disclosure] LEENO Industrial (058470) – New Facility Investment / 2024-11-08

Related Posts

  • [Disclosure] Hanwha Aerospace (012450) – Other Management Matters / 2025-04-30 Disclosures
  • [Disclosure] Celltrion (068270) – Approval of US FDA Marketing Authorization for Avtozma (CT-P47, Actemra Biosimilar) / 2025-01-31 Disclosures
  • [Disclosure] ISU PETASYS (007660) – Decision on Acquisition of Equity-Related Bonds / 2025-01-23 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Supply Contract / 2025-06-26 Disclosures
  • [Disclosure] Hanwha Systems (272210) – (Corrected) Decision on Acquisition of Equity-Related Debt Securities / 2024-06-17 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – New Facility Investment / 2024-09-25 Disclosures
  • [Research] Samsung Electronics (005930) – Eugene Investment & Securities | Memory Pricing Power · LTA Negotiations · Shareholder Return Outlook / 2026-07-06 RESEARCH
  • [Disclosure] Hanwha Aerospace (012450) – Other Management Matters / 2025-08-29 Disclosures
  • [Disclosure] Hanmi Semiconductor (042700) – Report on Reasons for Holding General Meeting of Shareholders on Concentrated Date / 2025-03-06 Semiconductors
  • [Research] SK hynix (000660 / SKHY) – iM Securities | Downcycle Earnings Defense · Range-Bound Share Price · Hold Rating / 2025-02-28 RESEARCH
  • [Disclosure] SK Square (402340) – Decision on Closure of Shareholders’ Register (Record Date) for Cash/In-Kind Dividend / 2025-01-23 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Media Reports (Unconfirmed) / 2024-05-02 Disclosures
  • [Disclosure] SK Square (402340) – Share Cancellation Decision / 2025-03-27 Semiconductors
  • [Disclosure] Celltrion (068270) – Marketing Authorization Granted by South Korean MFDS for Omlyclo (CT-P39, Xolair Biosimilar) / 2024-06-24 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme